Ikarian Capital’s Lexeo Therapeutics LXEO Stock Holding History

Ikarian Capital’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.39M	Hold	513,011	–	–	0.26%	82
2026 Q1	$2.94M	Hold	513,011	–	–	0.24%	82
2025 Q4	$5.09M	Sell	513,011 -54,590	-10%	-$498K	0.4%	62
2025 Q3	$3.77M	Buy	567,601 +17,572	+3%	+$85K	0.38%	70
2025 Q2	$2.21M	Hold	550,029	–	–	0.42%	65
2025 Q1	$1.91M	Buy	550,029 +50,728	+10%	+$225K	0.24%	70
2024 Q4	$3.29M	Buy	499,301 +242,085	+94%	+$1.91M	0.45%	63
2024 Q3	$2.33M	Buy	+257,216	New	+$3.07M	0.32%	70

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Ikarian Capital's LXEO Position: Q2 2026 in Review

Ikarian Capital held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 513,011 shares worth $2.39M. The position accounts for 0.26% of the portfolio, ranked #82.

Ikarian Capital first reported a position in LXEO in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.09M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Ikarian Capital held 513,011 shares of Lexeo Therapeutics worth $2.39M as of Q2 2026.
Ikarian Capital left its Lexeo Therapeutics share count unchanged in Q2 2026.
Lexeo Therapeutics made up 0.26% of Ikarian Capital's portfolio in Q2 2026, its #82 holding.
Ikarian Capital first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 8 quarters since.
Ikarian Capital's Lexeo Therapeutics position peaked at $5.09M in Q4 2025.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.